Spending in 2011 grew at 4.6% among employer-sponsored insurance plans
seems to be the rate of growth. And, after declining, year over year, in 2009 and 2010, that rate has now ticked upward, according to a report from the Health Care Cost Institute (HCCI; Washington, DC). Growth in 2009 was 5.8%; in 2010, 3.8%. The estimated total for employer-sponsored plans (ESIs) was $709.2 billion, representing approximately 40 million covered lives (HCCI’s 2010 report’s basis was 33 million lives; the 2010 figures have been adjusted to reflect the changing basis.)
For per-capita expenditures, HCCI segments costs by four categories: inpatient facility; outpatient facility (visits or other); professional procedures (physician and nonphysician); and prescriptions. The one category that is not contributing substantially to healthcare cost growth is prescriptions: HCCI estimates this growth at 1% in 2011, and it represents $773 in per capita terms. Professional procedures is the largest single category, with $1,566 per capita expense; it grew by 4.5% in 2011. The other two categories: inpatient, $963 (up 4.8%); and outpatient, $1,245 (up 6.8%). The overall per-capita total is $4,547. Out-of-pocket expenditures by individuals totaled $735, representing 16.2% of the per-capita total; the rest is covered by insurers.
Looking specifically at prescription trends, HCCI found that beneficiaries averaged 9.2 prescriptions, of which 1.9 were branded and 7.2 (approximately) were generic. Branded use declined by 12.9%, but spending rose 2.4%. Generic use rose 3.4%, but spending declined 4.0%.
HCCI is a year-old, independent nonprofit, apparently funded by insurance companies (Instittue literature refers to data providers Aetna, Humana, Kaiser Permanente and UnitedHealthcare), but governed by a board of healthcare policy specialists.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.